. (a) IL-33 expression in TAMs, tumour endothelial cells (ECs), CAFs and lymphocytes (LYs). P29 tumour ;ssues were double immunostained with an an;-IL-33 an;body and either an an;-F4/80, an;-CD31, an;-smooth muscle ac;n (αSMA) or an;-CD3 an;body. The arrowhead in each panel represents TAM, EC, CAF or LY. (b) IL-33 expression in EGFP-P29 tumour ;ssues. P29 cells expressing EGFP (EGFP-P29) were subcutaneously injected into B6-wild-type mice. The tumour ;ssues were stained with an an;-IL-33 an;body. Scale bars, 50 μm. Supplementary Fig. 6 . Effect of various cytokines on IL-33 mRNA expression in P29 cells. P29 cells were treated with the indicated cytokine at various concentra;ons for 2 days or at 10 ng/ml for up to 3 days. Total RNA was isolated and subjected to qRT-PCR analysis. Effect of IL-33 (a), IL-6 (b) and TRAIL (c). 
